The role of protein-linked oligosaccharide in the bilayer stabilization activity of glycophorin A for dioleoylphosphatidylethanolamine liposomes

Pinnaduwage, Purnima; Huang, Leaf

doi:10.1016/0005-2736(89)90278-2

Cited by 23 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different formulations of liposomes interact with cell surfaces via a variety of mechanisms. Two major pathways for interaction are by endocytosis or by direct fusion with the cell membrane [41,[49][50][51][52][53][54]. Preliminary data suggest that nucleic acids delivered in vitro and in vivo using complexes developed in our lab enter the cell by direct fusion (Figure 6).…”

Section: Overall Charge Of Complexes and Entry Into The Cellmentioning

confidence: 99%

Optimization of Nonviral Gene Therapeutics Using Bilamellar Invaginated Vesicles

Templeton¹

2015

Gene and Cell Therapy

View full text Add to dashboard Cite

Bilamellar invaginated vesicles (BIVs) are unique liposomal nanoparticles (NPs) that are highly efficient vehicles for intravenous (iv) delivery of encapsulated therapeutics including plasmid DNA. Systemic administration of therapeutics is required to effectively treat or cure metastatic cancer, certain cardiovascular diseases, and other acquired or inherited diseases. In addition to having extended half-life and stability in circulation, BIVs are nontoxic, nonimmunogenic, biodegradable and can be repeatedly administered without losing potency. Furthermore, BIVs encapsulating therapeutic agents can be modified to specifically enter the disease cells using small molecules that mimic beta turns incorporated on the surface of BIV complexes while focusing biodistribution by bypassing uptake in non-target organs and tissues using reversible masking. These modifications do not alter the unique properties of the BIV delivery system that provide for its robust treatment of disease demonstrated in small and large animal models and in Phase I clinical trials. This review will cover the unique properties of BIVs, including its fusogenic entry into cells and its ability to penetrate tight barriers in vivo. Methods to further improve the overall delivery-expression system including further purification of plasmid DNA to eliminate colanic acid from all current commercially produced preparations, and enhanced or prolonged expression provided by plasmid design will also be discussed.

show abstract

Section: Overall Charge Of Complexes and Entry Into The Cellmentioning

confidence: 99%

Optimization of Nonviral Gene Therapeutics Using Bilamellar Invaginated Vesicles

Templeton¹

2015

Gene and Cell Therapy

View full text Add to dashboard Cite

show abstract

“…Different formulations of liposomes interact with cell surfaces via a variety of mechanisms. Two major pathways for interaction are by endocytosis or by direct fusion with the cell membrane [28,[30][31][32][33][34][35]. Preliminary data suggest that nucleic acids delivered in vitro and in vivo using complexes developed in our lab enter the cell by direct fusion (Fig.…”

Section: Overall Charge Of Complexes and Entry Into The Cellmentioning

confidence: 99%

Nonviral Delivery for Genomic Therapy of Cancer

Templeton

2008

World j. surg.

View full text Add to dashboard Cite

We have developed improved liposomal nanoparticles that efficiently condense nucleic acids, proteins, viruses, drugs, and mixtures of these agents on the interior of bilamellar invaginated structures (BIVs) produced by a novel extrusion procedure. The liposomal complexes have extended half-life in the circulation, serum stability, and broad biodistribution; are targetable to specific organs and cell types; can penetrate through tight barriers in several organs; are fusogenic with cell membranes and avoid endosomes; are optimized for nucleic acid:lipid ratio and colloidal suspension in vivo; can be size fractionated to produce totally homogeneous populations of complexes prior to injection; are nontoxic, nonimmunogenic, and can be repeatedly administered; and they are stable in liquid suspensions and freeze-dried formulations. We can add specific ligands either by ionic interactions or by covalent attachments to the surface of these nucleic acid-liposome complexes to accomplish targeted delivery to specific cell surface receptors. Furthermore, the charge on the surface of these complexes can be modified to avoid uptake by nontarget cells using our novel technology called "reversible masking." We have also achieved high-dose systemic delivery of these complexes without toxicity in vivo by further purification of plasmid DNA. At present, these complexes are injected intravenously into patients in clinical trials to treat lung cancer and will be used in upcoming trials to treat breast, pancreatic, and head and neck cancers. Notably, BIV complexes are being injected intravenously into patients with non-small-cell lung carcinoma who have failed to respond to chemotherapy. These patients are living longer and have demonstrated objective responses, including tumor regression.

show abstract

“…1.4A) or by direct fusion with the cell membrane ( Fig. 1.4B) (Behr et al, 1989;Felgner and Ringold, 1989;Pinnaduwage and Huang, 1989; Leventis and Silvius, 1990;Rose, Buonocore, and Whitt, 1991;Loeffler and Behr, 1993;Gustafsson et al, 1995). Many formulations, including PEGylated complexes with attached ligands used for targeted delivery, enter cells through the endocytic pathway.…”

Section: Mechanisms Of Cell Entrymentioning

confidence: 99%

Alternative Strategies for Targeted Delivery of Nucleic Acid–Liposome Complexes

Templeton

2002

Vector Targeting for Therapeutic Gene Delivery

View full text Add to dashboard Cite

The role of protein-linked oligosaccharide in the bilayer stabilization activity of glycophorin A for dioleoylphosphatidylethanolamine liposomes

Cited by 23 publications

References 35 publications

Optimization of Nonviral Gene Therapeutics Using Bilamellar Invaginated Vesicles

Optimization of Nonviral Gene Therapeutics Using Bilamellar Invaginated Vesicles

Nonviral Delivery for Genomic Therapy of Cancer

Alternative Strategies for Targeted Delivery of Nucleic Acid–Liposome Complexes

Contact Info

Product

Resources

About